Team develops method to better identify genes involved in diseases

April 6, 2015, Agency for Science, Technology and Research (A*STAR), Singapore
genes
This image shows the coding region in a segment of eukaryotic DNA. Credit: National Human Genome Research Institute

Scientists at A*STAR's Genome Institute of Singapore (GIS) have developed a new technique that simplifies the task of identifying the precise DNA mutations that cause disease, which lays the groundwork for the development of new drugs and new ways of diagnosing diseases.

It is generally extremely difficult to design for diseases such as diabetes or rheumatoid arthritis (for example), because we do not know which molecules in the body the drugs should target. This is where disease-causing DNA come in. If we can pinpoint the genetic mutations that cause a particular disease, we can associate those mutations with specific proteins, and then design drugs to block or activate those proteins. We can also measure the activity of proteins identified in this manner to diagnose diseases more accurately, which is a major goal of precision medicine.

A team of scientists, led by Dr Shyam Prabhakar, Associate Director for Integrated Genomics at GIS, developed a new genetic analysis technique called the Genotype-independent Signal Correlation and Imbalance (G-SCI) that senses specific chemical changes within the genome and connects them to nearby . They then showed that mutations associated with the were also likely to cause disease. The G-SCI test was validated in a study of 57 individuals and is reported in the scientific journal, Nature Methods.

When combined with the chemical profiling strategy used in this study, the G-SCI test is 10 times more sensitive than existing methods at identifying detrimental gene mutations. The study's co-lead, Dr Ricardo del Rosario from GIS, said, "The G-SCI test is transformative – instead of examining gene expression correlations in 500 individuals, we can get away with histone acetylation analysis of a mere 50 to 60. This reduces the number of test subjects needed to conclude each study and gives us the ability to look into multiple diseases."

Dr Jeremie Poschmann from GIS, the other co-lead of the study, highlighted another benefit of the new approach: "Instead of using genome sequencing, we can use the histone acetylation sequencing data from our method to detect DNA mutations. This saves us a huge amount of time, effort and resources."

Prof Bing Ren of the Ludwig Institute of Cancer Research and the Department of Cellular and Molecular Medicine, University of California, San Diego (UCSD) said, "This is an exciting study that sets a new benchmark for genetic analysis of gene regulation. The method greatly enhances our ability to interpret the and will benefit research into the genetic basis of diseases."

The scientists validated the efficiency of the new test and were able to identify links to certain . "We have found a strong association between mutations that perturbed the genome's chemical state and those that caused . That's when we knew we had hit the bulls-eye with the G-SCI test," said Dr Prabhakar.

"This work provides important new tools for linking genetic variation to variation in chromatin function, and provides compelling evidence for the central role of this type of genetic variation in human disease," commented Prof Jonathan Pritchard from Stanford University, who is also an Investigator at the Howard Hughes Medical Institute.

"I am thrilled by this new method with superior precision for identifying disease-causing mutations. The G-SCI method innovatively utilises epigenetic information to select regions of the human genome for disease association analysis. As we see bigger and more complex datasets, the community will face the forthcoming challenges of analysing big data. This method has expanded our arsenal of computational analytics capabilities at the Genome Institute of Singapore," said Prof Huck-Hui Ng, Executive Director of GIS.

Explore further: Team identifies mutations that may enable earlier diagnosis of colorectal cancer recurrence

More information: "Sensitive mapping of chromatin‐altering polymorphisms reveals molecular drivers of autoimmune disease" Nature Methods

Related Stories

Team identifies mutations that may enable earlier diagnosis of colorectal cancer recurrence

March 25, 2015
A multi-disciplinary team of doctors and scientists from Singapore has characterised the genetic changes associated with the spread of colorectal cancer to the liver. This finding is significant in helping to develop personalised ...

Scientists develop genome-wide mutation hunting computational software for genomic medicine

August 19, 2014
Phen-Gen is the first computer analysis software that cross-references a patient's symptoms and a person's genome sequence, to better aid doctors in diagnosing diseases.

LoFreq: Ultrafast detection of microbe and cancer cell mutations

March 7, 2013
Scientists at A*STAR's Genome Institute of Singapore (GIS) have developed a novel technique to precisely monitor and study the evolution of micro-organisms such as viruses and bacteria. This is an extremely important capability ...

Researchers develop expert systems for identifying treatment targets for cancer and rare diseases

February 13, 2015
In recent months, several national initiatives for personalized medicine have been announced, including the recently launched precision medicine initiative in the US, driven by rapid advances in genomic technologies and with ...

Researchers devise new method to identify disease markers

March 3, 2015
UCLA life scientists have created an accurate new method to identify genetic markers for many diseases—a significant step toward a new era of personalized medicine, tailored to each person's DNA and RNA.

Researchers confirm whole-genome sequencing can successfully identify cancer-related mutations

December 23, 2014
UT Southwestern Medical Center cancer researchers have demonstrated that whole-genome sequencing can be used to identify patients' risk for hereditary cancer, which can potentially lead to improvements in cancer prevention, ...

Recommended for you

Progress in genetic testing of embryos stokes fears of designer babies

November 16, 2018
Recent announcements by two biotechnology companies have stoked fears that designer babies could soon be an option for those who can afford to pick and choose which features they want for their offspring. The companies, MyOme ...

Gene editing possible for kidney disease

November 16, 2018
For the first time scientists have identified how to halt kidney disease in a life-limiting genetic condition, which may pave the way for personalised treatment in the future.

DICE: Immune cell atlas goes live

November 15, 2018
Compare any two people's DNA and you will find millions of points where their genetic codes differ. Now, scientists at La Jolla Institute for Immunology (LJI) are sharing a trove of data that will be critical for deciphering ...

Ashkenazi Jewish founder mutation identified for Leigh Syndrome

November 15, 2018
Over 30 years ago, Marsha and Allen Barnett lost their sons to a puzzling childhood disease that relentlessly attacked their nervous systems and sapped their energy. After five-year-old Chuckie died suddenly in 1981, doctors ...

Drug candidate may recover vocal abilities lost to ADNP syndrome

November 15, 2018
Activity-dependent neuroprotective protein syndrome (ADNP syndrome) is a rare genetic condition that causes developmental delays, intellectual disability and autism spectrum disorder symptoms in thousands of children worldwide. ...

The puzzle of a mutated gene lurking behind many Parkinson's cases

November 15, 2018
Genetic mutations affecting a single gene play an outsized role in Parkinson's disease. The mutations are generally responsible for the mass die-off of a set of dopamine-secreting, or dopaminergic, nerve cells in the brain ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.